STOCK TITAN

Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Treace Medical Concepts, Inc. is a leading orthopaedic medical device company specializing in innovative solutions for the surgical management of bunion deformities. With a commitment to excellence, the company brings breakthrough technologies to the high-growth $1.1 billion US market for foot and ankle surgical products.

Treace's flagship product, the Lapiplasty® 3D Bunion Correction™ procedure, addresses the root cause of bunions by correcting all planes of the deformity. This patented procedure not only improves patient outcomes but also allows for a quicker return to an active lifestyle.

The company operates as a single segment, focusing on the design, manufacturing, and marketing of medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals. Their mission is to assist foot and ankle physicians in enhancing patient outcomes and reducing healthcare costs, while also providing a rewarding experience for their employees and exceptional returns for shareholders.

In recent news, Treace Medical Concepts announced their participation in the upcoming J.P. Morgan Healthcare Conference, showcasing new SpeedPlate™ configurations, and the full commercial release of the Micro-Lapiplasty™ System. Additionally, they have initiated a limited clinical release of the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company also focuses on educational outreach to build awareness and reduce stigma around bunion deformities.

Treace Medical Concepts has also partnered to support pickleball players with bunions and related midfoot deformities, helping them to 'get back on their feet' and onto the court. Such initiatives highlight Treace's dedication to improving the lives of individuals affected by foot health issues.

Rhea-AI Summary

Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark Hair will join a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at approximately 4:15 PM ET. This discussion will focus on the company’s innovative Lapiplasty® 3D Bunion Correction™ procedure, designed to improve surgical treatment for bunions. A live webcast and replay will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI), a pioneering orthopaedic medical device company, announced new data will be presented at the 2021 AOFAS Annual Meeting on September 22-25. The presentation will feature an interim analysis from the ALIGN3D™ clinical study, which evaluates the Lapiplasty® 3D Bunion Correction™ procedure. Lead author Dr. Dane Wukich will discuss outcomes from this multicenter study, focusing on patient recovery and radiographic results. The study aims to confirm effective bunion correction over a 24-month follow-up with 173 enrolled patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported Q2 2021 revenue of $20.7 million, marking a 167% increase compared to Q2 2020. The gross margin improved to 80.9%, up 780 basis points year-over-year. The rise in revenue is attributed to more Lapiplasty® procedure kits sold and a growing customer base. Despite higher revenues, the net loss for the quarter increased to ($5.1 million), or ($0.10) per share, compared to ($2.1 million), or ($0.06) per share last year. The company anticipates full-year revenue between $90 million and $95 million, reflecting a growth of 57% to 65%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) will announce its second quarter 2021 financial results on August 5, 2021, after the market closes. A conference call led by management will commence at 4:30 p.m. ET to discuss the results. The company is known for its Lapiplasty® 3D Bunion Correction™ system, which addresses bunion deformities. Investors can join the call by dialing (888) 708-0264 or (720) 405-2122 for international access. The call will also be webcasted live and archived on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences earnings
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported significant first-quarter 2021 financial results, achieving $18.7 million in revenue, a 66.2% increase from last year. Gross margin improved to 82.2%, up 340 basis points year-over-year, driven by higher sales of the Lapiplasty Procedure Kits. Despite a net loss of $2.6 million or ($0.07) per share, the company anticipates a full-year revenue range of $87 million to $92 million, indicating 52% to 60% growth from fiscal 2020. Cash and equivalents stood at $16.2 million as of March 31, 2021, excluding IPO proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced positive interim results from the ALIGN3D clinical study at the ACFAS Annual Scientific Conference. The study evaluated 128 participants undergoing the Lapiplasty 3D Bunion Correction procedure. Key findings include an early weight-bearing average of 8.3 days, a 1.4% recurrence rate at 12 months, and significant improvements in patient-reported pain and quality of life. The study aims to assess long-term outcomes and has completed enrollment, with final results expected in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced it will release its Q1 2021 financial results on May 25, 2021, after market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Investors can access the call by dialing (833) 730-3977 (domestic) or (720) 405-2122 (international) with Conference ID: 1157038. The company specializes in surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ system, aimed at enhancing patient recovery and addressing the root causes of bunion deformities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
conferences earnings
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced that interim results of its ALIGN3D™ clinical study will be presented at the ACFAS Scientific Conference on May 19, 2021. The study evaluates the effectiveness of the Lapiplasty® 3D Bunion Correction™ in treating hallux valgus, involving 173 patients across seven sites. Key endpoints include recurrence of the bunion deformity and patient-reported outcomes after two years. The final follow-up for primary endpoints is expected in the first half of 2023, indicating ongoing commitment to advancing surgical treatment standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced its upsized initial public offering pricing of 11,250,000 shares at $17.00 each, aiming for gross proceeds of approximately $106.3 million. Of these shares, 6,250,000 will be sold by Treace, while 5,000,000 are from selling stockholders. Additionally, underwriters have a 30-day option to purchase up to 1,687,500 additional shares. Trading is set to commence on April 23, 2021, with the closing expected by April 27, 2021, following standard conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI) announced an upsized initial public offering (IPO) of 11,250,000 shares, priced at $17.00 each, aiming to raise approximately $106.3 million before expenses. Of these, 6,250,000 shares are offered by Treace while 5,000,000 shares are from selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 1,687,500 shares. Trading on the Nasdaq is set to start on April 23, 2021, with the closing anticipated on April 27, 2021, pending customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $6.96 as of December 20, 2024.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 433.0M.

What does Treace Medical Concepts, Inc. specialize in?

Treace Medical Concepts specializes in innovative solutions for the surgical management of bunion deformities.

What is the Lapiplasty® 3D Bunion Correction™ procedure?

The Lapiplasty® 3D Bunion Correction™ procedure is designed to correct all planes of a bunion deformity, addressing its root cause and allowing for quick patient recovery.

What recent products has Treace Medical Concepts released?

Treace has released the Micro-Lapiplasty™ System, SpeedPlate™ configurations, and introduced the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation.

How does Treace Medical Concepts support the foot and ankle surgical market?

Treace supports this market by designing, manufacturing, and marketing medical devices that enhance patient outcomes and reduce healthcare costs.

When is Treace Medical Concepts presenting at the J.P. Morgan Healthcare Conference?

Treace Medical Concepts is presenting at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 pm Pacific Time.

What is Treace's focus regarding patient outcomes?

Treace aims to improve patient outcomes by providing innovative surgical solutions that address the root cause of bunion deformities and allow quicker recovery times.

Who are the primary customers of Treace Medical Concepts?

The primary customers include physicians, surgeons, ambulatory surgery centers, and hospitals.

What ethical standards does Treace Medical Concepts adhere to?

Treace prides itself on operating with the highest standards of ethical conduct in all its business operations.

What is the company’s mission?

The mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for employees and exceptional returns for shareholders.

How is Treace Medical Concepts involved in community outreach?

Treace is actively involved in outreach and education efforts to build awareness, reduce stigma, and correct misconceptions about bunion deformities.

Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

TMCI Stock Data

432.96M
45.77M
24.82%
64.33%
4.79%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PONTE VEDRA